CVA Family Office’s Aurinia Pharmaceuticals AUPH Stock Holding History

CVA Family Office’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.88K	Hold	194	–	–	﹤0.01%	1422
2025 Q4	$3.09K	Sell	194 -90	-32%	-$1.28K	﹤0.01%	936
2025 Q3	$3.14K	Buy	284 +90	+46%	+$983	﹤0.01%	945
2025 Q2	$1.64K	Hold	194	–	–	﹤0.01%	1018
2025 Q1	$1.56K	Hold	194	–	–	﹤0.01%	1038
2024 Q4	$1.74K	Hold	194	–	–	﹤0.01%	1007
2024 Q3	$1.42K	Hold	194	–	–	﹤0.01%	1026
2024 Q2	$1.11K	Buy	+194	New	+$1.02K	﹤0.01%	1060
2024 Q1	–	Sell	-139	Closed	-$1.25K	–	1057
2023 Q4	$1.25K	Buy	+139	New	+$1.15K	﹤0.01%	956

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CVA Family Office's AUPH Position: Q1 2026 in Review

CVA Family Office held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 194 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

CVA Family Office first reported a position in AUPH in Q4 2023 and has held it in 9 quarters since. The position peaked at $3.14K in Q3 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

CVA Family Office held 194 shares of Aurinia Pharmaceuticals worth $2.88K as of Q1 2026.
CVA Family Office left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1422 holding.
CVA Family Office first reported a position in Aurinia Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
CVA Family Office's Aurinia Pharmaceuticals position peaked at $3.14K in Q3 2025.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.